Purdue Pharma, the maker of OxyContin, has proposed a settlement plan valued at over $7 billion to resolve thousands of lawsuits related to the opioid crisis. This plan will be presented before a judge on Friday, which could pave the way for various groups—including local governments and individuals affected by addiction—to vote on its acceptance.
This month saw 49 states agreeing to the proposal. The lone exception is Oklahoma, which has already reached a separate settlement with the company.
The decision on whether to proceed with the nationwide settlement could be made by U.S. Bankruptcy Court Judge Sean Lane as early as Friday. The proposal is the result of extensive negotiations among the company, various suing parties, and representatives of the Sackler family, who own Purdue Pharma.
If Lane moves the plan forward as it’s been presented, government entities, emergency room doctors, insurers, families of children born into withdrawal from the powerful prescription painkiller, individual victims and their families and others would have until Sept. 30 to vote on whether to accept the deal.
The settlement is a way to avoid trials with claims from states alone that total more than $2 trillion in damages.
If approved, the settlement would be among the largest in a wave of lawsuits over the past decade as governments and others sought to hold drugmakers, wholesalers and pharmacies accountable for the opioid epidemic that started rising in the years after OxyContin hit the market in 1996. The other settlements together are worth about $50 billion, and most of the money is to be used to combat the crisis.
In the early 2000s, most opioid deaths were linked to prescription drugs, including OxyContin. Since then, heroin and then illicitly produced fentanyl became the biggest killers. In some years, the class of drugs was linked to more than 80,000 deaths, but that number dropped sharply last year.
Last year, the U.S. Supreme Court rejected a version of Purdue’s proposed settlement. The court found it was improper to protect members of the Sackler family from lawsuits over opioids, even though they themselves were not filing for bankruptcy protection.
In the new version, groups that don’t opt in to the settlement would still have the right to sue members of the wealthy family whose name once adorned museum galleries around the world and programs at several prestigious U.S. universities.
Under the plan, the Sackler family members would give up ownership of Purdue. They resigned from the company’s board and stopped receiving distributions from its funds before the company’s initial bankruptcy filing in 2019. The remaining entity would get a new name and its profits would be dedicated to battling the epidemic.
Most of the money would go to state and local governments to address the nation’s addiction and overdose crisis, but potentially more than $850 million would go directly to individual victims. That makes it different from the other major settlements.
The payments would not begin until after a hearing, likely in November, during which Judge Lane would be asked to approve the entire plan if enough of the affected parties agree.
